Morpholino

MO1-notch2

ID
ZDB-MRPHLNO-041207-6
Name
MO1-notch2
Previous Names
  • MO-notch2-1 (1)
Target
Sequence
5' - AGGTGAACACTTACTTCATGCCAAA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
designed to bind to exon-intron region, predicted to generate a premature stop codon after the last exon 7 codon, thus deleting the entire ankyrin repeat domain.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-notch2
Phenotype
Phenotype resulting from MO1-notch2
Phenotype of all Fish created by or utilizing MO1-notch2
Phenotype Fish Conditions Figures
thoracic duct absent, abnormal WT + MO1-notch2 standard conditions Fig. 1 from Geudens et al., 2010
opercle curved, abnormal WT + MO1-notch2 standard conditions Fig. 1 with image from Zuniga et al., 2010
opercle decreased width, abnormal WT + MO1-notch2 standard conditions Fig. 1 with image from Zuniga et al., 2010
thoracic duct wholeness, abnormal WT + MO1-notch2 standard conditions Fig. 1 from Geudens et al., 2010
palatoquadrate cartilage truncated, abnormal WT + MO1-notch2 standard conditions Fig. 1 with image from Zuniga et al., 2010
hyosymplectic cartilage elongated, abnormal WT + MO1-notch2 standard conditions Fig. 1 with image from Zuniga et al., 2010
lymphangiogenesis disrupted, abnormal WT + MO1-notch2 standard conditions Fig. 1 from Geudens et al., 2010
hyosymplectic cartilage deformed, abnormal WT + MO1-notch2 standard conditions Fig. 1 with image from Zuniga et al., 2010
endocrine pancreas decreased size, abnormal nl1Tg + MO1-notch2 standard conditions Fig. S10 from O'Hare et al., 2016
enteroendocrine cell differentiation disrupted, abnormal nl1Tg + MO1-notch2 standard conditions Fig. S10 from O'Hare et al., 2016
endocrine pancreas EGFP expression decreased distribution, abnormal nl1Tg + MO1-notch2 standard conditions Fig. S10 from O'Hare et al., 2016
endocrine pancreas development disrupted, abnormal nl1Tg + MO1-notch2 standard conditions Fig. S10 from O'Hare et al., 2016
response to glucose decreased process quality, abnormal jh1Tg; jh2Tg + MO1-notch2 chemical treatment by environment: glucose Fig. 4 from O'Hare et al., 2016
pancreatic B cell decreased amount, abnormal jh1Tg; jh2Tg + MO1-notch2 standard conditions Fig. 2 from O'Hare et al., 2016
pancreatic B cell decreased amount, abnormal jh1Tg; jh2Tg + MO1-notch2 chemical treatment by environment: glucose Fig. 4 from O'Hare et al., 2016
glucose homeostasis disrupted, abnormal jh1Tg; jh2Tg + MO1-notch2 chemical treatment by environment: glucose Fig. S15 from O'Hare et al., 2016
glucose homeostasis disrupted, abnormal jh1Tg; jh2Tg + MO1-notch2 control Fig. S15 from O'Hare et al., 2016
pancreatic B cell decreased area, abnormal jh1Tg; jh2Tg + MO1-notch2 standard conditions Fig. 1 from O'Hare et al., 2016
symplectic decreased size, abnormal edn1tf216b/tf216b + MO1-notch2 standard conditions Fig. 6 with image from Zuniga et al., 2010
ceratohyal cartilage decreased size, abnormal edn1tf216b/tf216b + MO1-notch2 standard conditions Fig. 6 with image from Zuniga et al., 2010
Meckel's cartilage morphology, abnormal edn1tf216b/tf216b + MO1-notch2 standard conditions Fig. 6 with image from Zuniga et al., 2010
Meckel's cartilage decreased size, abnormal edn1tf216b/tf216b + MO1-notch2 standard conditions Fig. 6 with image from Zuniga et al., 2010
pancreatic B cell regeneration decreased rate, abnormal jh4Tg + MO1-notch2 chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Fig. 5 from O'Hare et al., 2016
Citations